Overview
- CEPI committed up to $20 million to build a scalable, rapid manufacturing process using Samsung Biologics’ mammalian cell‑based infrastructure and mature quality systems.
- Samsung Biologics joined CEPI’s Vaccine Manufacturing Facility Network as a preferred partner and the network’s first East Asian member.
- The company guaranteed access to up to 50 million finished vaccine doses and drug substance for up to one billion doses for conversion in a pandemic.
- A WHO‑recommended wild‑type H5 influenza simulation will test end‑to‑end readiness from antigen development to finished product and inform regulatory dossier preparation.
- The arrangement reserves supply for underserved LMICs while accommodating Korea’s needs under CEPI’s Equitable Access Policy, with potential future work on tech transfer and regulatory readiness.